For patients with KRAS wild-type NSCLC, however, ICIs did not prolong OS over that with chemotherapy (HR = 0.88 [95% CI = 0.68–1.13], P = 0.30) (Figure 2B). Here, KRAS is linked to non-small cell lung carcinoma.